4.4 Article

Methods for the inclusion of real-world evidence in network meta-analysis

期刊

BMC MEDICAL RESEARCH METHODOLOGY
卷 21, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12874-021-01399-3

关键词

Network meta-analysis; Randomised controlled trial; Real-world evidence

资金

  1. Innovative Medicines Initiative Joint Undertaking [115546]
  2. European Union
  3. UK Medical Research Council [MR/R025223/1]
  4. Medical Research Council (MRC) Methodology Research Programme [MR/L009854/1]
  5. NIHR Senior Investigator Emeritus [NI-SI-0512-10159]
  6. National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre (NIHR Greater Manchester PSTRC)

向作者/读者索取更多资源

This study investigated methods for including real-world evidence (RWE) in Network Meta-Analysis (NMA) and its impact on effectiveness estimates uncertainty levels. The 'power prior' method significantly affected the overall uncertainty levels by incorporating RWE, while hierarchical models effectively managed heterogeneity between study designs, albeit increasing the uncertainty levels.
Background: Network Meta-Analysis (NMA) is a key component of submissions to reimbursement agencies world-wide, especially when there is limited direct head-to-head evidence for multiple technologies from randomised controlled trials (RCTs). Many NMAs include only data from RCTs. However, real-world evidence (RWE) is also becoming widely recognised as a valuable source of clinical data. This study aims to investigate methods for the inclusion of RWE in NMA and its impact on the level of uncertainty around the effectiveness estimates, with particular interest in effectiveness of fingolimod. Methods: A range of methods for inclusion of RWE in evidence synthesis were investigated by applying them to an illustrative example in relapsing remitting multiple sclerosis (RRMS). A literature search to identify RCTs and RWE evaluating treatments in RRMS was conducted. To assess the impact of inclusion of RWE on the effectiveness estimates, Bayesian hierarchical and adapted power prior models were applied. The effect of the inclusion of RWE was investigated by varying the degree of down weighting of this part of evidence by the use of a power prior. Results: Whilst the inclusion of the RWE led to an increase in the level of uncertainty surrounding effect estimates in this example, this depended on the method of inclusion adopted for the RWE. 'Power prior' NMA model resulted in stable effect estimates for fingolimod yet increasing the width of the credible intervals with increasing weight given to RWE data. The hierarchical NMA models were effective in allowing for heterogeneity between study designs, however, this also increased the level of uncertainty. Conclusion: The 'power prior' method for the inclusion of RWE in NMAs indicates that the degree to which RWE is taken into account can have a significant impact on the overall level of uncertainty. The hierarchical modelling approach further allowed for accommodating differences between study types. Consequently, further work investigating both empirical evidence for biases associated with individual RWE studies and methods of elicitation from experts on the extent of such biases is warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据